Atai Life Sciences (ATAI) announced the pricing of a registered underwritten offering of 23.725M common shares, at a price of $5.48 per share. The offering is expected to close on October 20. Jefferies is the lead bookrunner for the offering. Berenberg Capital Markets is also acting as passive bookrunner for the offering. Oppenheimer & Co. and Canaccord Genuity are acting as co-managers for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- ATAI Life Sciences’ BPL-003 Receives FDA Breakthrough Designation
- Atai Life Sciences announces common shares offering, no amount given
- Psychedelic: Needham initiates coverage of atai, GH Research, MindMed
- Atai Life Sciences initiated with a Buy at Needham
- ATAI Life Sciences to Acquire Beckley Psytech